Evidence map›Paper›PMID 41070200›Full record

ReviewImmunoTargets and therapy2025

2B4/CD244 Signaling in Immune Regulation and Its Role in Infection, Cancer, and Immune Tolerance.

Chao Yan, Peng Lu, Yuzhu Jiang, Shu Miao, Lichun Zhao, Xiaoyan Xu

Abstract readReview
In one paragraph

Review in ImmunoTargets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chao Yan *Department of Immunology, Binzhou Medical University, Yantai, Shandong, 264003, People's Republic of China.
Peng Lu *School of Life Sciences, Ludong University, Yantai, Shandong, 264025, People's Republic of China.
Yuzhu Jiang *Department of Immunology, Binzhou Medical University, Yantai, Shandong, 264003, People's Republic of China.
Shu MiaoR&D Department, Hainan Cell Medical Technology Co., Ltd, Haikou, Hainan, 570100, People's Republic of China.
Lichun ZhaoCollege of Pharmaceutical Sciences, Guizhou University of Traditional Chinese Medicine, Guiyang, 550025, People's Republic of China.
Xiaoyan XuDepartment of Immunology, Binzhou Medical University, Yantai, Shandong, 264003, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

2B4 (CD244), the fourth member of the signaling lymphocyte activation molecule (SLAM) family, is expressed by virtually all human and murine hematopoietic lineages and functions as a context-dependent activating or inhibitory receptor. This review provides a comprehensive update on the gene organization, molecular architecture, glycosylation patterns, and alternatively spliced isoforms of 2B4, highlighting how these structural variables dictate ligand (CD48) affinity and downstream signaling outcome. The roles of 2B4 in natural killer (NK) cells, CD8

Indexed as

2B4immune activationimmune toleranceinfectious diseaseneoplastic disease

Identifiers

PMID41070200
PMCPMC12506779

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.